Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis : final ten year results from the UK multiple sclerosis risk sharing scheme

Tools
- Tools
+ Tools

Palace, Jacqueline, Duddy, Martin, Lawton, Michael, Bregenzer, Thomas, Zhu, Feng, Boggild, Mike, Piske, Benjamin, Robertson, Neil P, Oger, Joel, Tremlett, Helen, Tilling, Kate, Ben-Shlomo, Yoav, Lilford, Richard and Dobson, Charles (2019) Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis : final ten year results from the UK multiple sclerosis risk sharing scheme. Journal of Neurology, Neurosurgery and Psychiatry, 90 (3). pp. 251-260. doi:10.1136/jnnp-2018-318360 ISSN 0022-3050.

[img]
Preview
PDF
WRAP-assessing-long-term-effectiveness-interferon-beta-glatiramer-acetate-multiple-sclerosis-Lilford-2018.pdf - Published Version - Requires a PDF viewer.
Available under License Creative Commons: Attribution-Noncommercial 4.0.

Download (643Kb) | Preview
[img] PDF
submitted proof after reviewer input .pdf - Accepted Version
Embargoed item. Restricted access to Repository staff only - Requires a PDF viewer.

Download (1435Kb)
Official URL: https://doi.org/10.1136/jnnp-2018-318360

Request Changes to record.

Abstract

Background

Because multiple sclerosis (MS) is a chronic disease causing disability over decades, it is crucial to know if the short-term effects of disease-modifying therapies reported in randomised controlled trials reduce long-term disability. This 10-year prospective observational study of disability outcomes (Expanded Disability Status Scale (EDSS) and utility) was set up, in conjunction with a risk-sharing agreement between payers and producers, to investigate this issue.

Methods

The outcomes of the UK treated patients were compared with a modelled untreated control based on the British Columbia MS data set to assess the long-term effectiveness of these treatments. Two complementary analysis models were used: a multilevel model (MLM) and a continuous Markov model.

Results

4862 patients with MS were eligible for the primary analysis (mean and median follow-up times 8.7 and 10 years). EDSS worsening was reduced by 28% (MLM), 7% (Markov) and 24% time-adjusted Markov in the total cohort, and by 31% (MLM) and 14% (Markov) for relapsing remitting patients. The utility worsening was reduced by 23%–24% in the total cohort and by 24%–31% in the RR patients depending on the model used. All sensitivity analyses showed a treatment effect. There was a 4-year (CI 2.7 to 5.3) delay to EDSS 6.0. An apparent waning of treatment effect with time was seen. Subgroup analyses suggested better treatment effects in those treated earlier and with lower EDSS scores.

Conclusions

This study supports a beneficial effect on long-term disability with first-line MS disease-modifying treatments, which is clinically meaningful. However the waning effect noted requires further study.

Item Type: Journal Article
Subjects: R Medicine > RC Internal medicine
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Population, Evidence & Technologies (PET)
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Multiple sclerosis -- Treatment, Interferon
Journal or Publication Title: Journal of Neurology, Neurosurgery and Psychiatry
Publisher: B M J Group
ISSN: 0022-3050
Official Date: 14 February 2019
Dates:
DateEvent
14 February 2019Published
7 July 2018Accepted
6 March 2018Submitted
Volume: 90
Number: 3
Page Range: pp. 251-260
DOI: 10.1136/jnnp-2018-318360
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access (Creative Commons)
Date of first compliant deposit: 1 April 2019
Date of first compliant Open Access: 2 April 2019
RIOXX Funder/Project Grant:
Project/Grant IDRIOXX Funder NameFunder ID
UNSPECIFIEDBiogen Idechttp://dx.doi.org/10.13039/100006314
UNSPECIFIEDMerck seronoUNSPECIFIED
UNSPECIFIEDBayerhttp://dx.doi.org/10.13039/100004326
UNSPECIFIEDTeva Pharmaceutical Industrieshttp://dx.doi.org/10.13039/100006259
10/55/01Health Technology Assessment programmehttp://dx.doi.org/10.13039/501100000664
Open Access Version:
  • Publisher

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us